EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Impact of Increased Use of Single-Inhaler Triple Therapies on COPD Exacerbation Rates, Mortality, and Total Costs: PROMETHEUS France

Gaëtan Deslee, Héloïse Russo, Caroline Fabry-Vendrand, David Koskas, Gabriel Thabut, John P Bell, Melissa Caplen, Prachi Devendra Bhatt, Jennifer Carioto, Bruce Pyenson, Pierre-Régis Burgel iD

International Journal of Chronic Obstructive Pulmonary Disease · 2025

DOI: 10.2147/copd.s539055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025. Verfasst von Gaëtan Deslee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pneumologie, INSERM UMRS-1250, Hospital Universitaire de Reims, Reims, France. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Bronchodilator Agents, Drug Costs, Adrenergic beta-2 Receptor Agonists. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveBronchodilator AgentsDrug CostsAdrenergic beta-2 Receptor AgonistsAdrenal Cortex HormonesNebulizers and VaporizersLungCholinergic AntagonistsHumansFranceAdministration, InhalationDisease ProgressionTreatment OutcomeTime FactorsModels, EconomicCost-Benefit AnalysisAgedMaleDrug Therapy, CombinationFemaleMiddle AgedSeverity of Illness IndexCost Savings

Stichwörter der Autor:innen

COPDpopulation modelsingle-inhaler triple therapy

Substanzen

Bronchodilator AgentsAdrenergic beta-2 Receptor AgonistsAdrenal Cortex HormonesCholinergic Antagonists

Autor:innen und Institutionen

  • Service de Pneumologie, INSERM UMRS-1250, Hospital Universitaire de Reims, Reims, France.
  • Astrazeneca, Medical Department, Courbevoie, France.
  • AstraZeneca, Global Respiratory & Immunology, BioPharmaceuticals Medical, Cambridge, UK.
  • Milliman,New York, NY, USA.
  • Service de Pneumologie, Hôpital Cochin, Assistance Publique Hôpitaux de Paris et Université Paris Cité, Institut Cochin, INSERM U1016, Paris, France.

ORCID-Profile: Pierre-Régis Burgel

Förderung

  • AstraZeneca

Zitieren

APA

Deslee, G., Russo, H., Fabry-Vendrand, C., Koskas, D., Thabut, G., Bell, J. P., Caplen, M., Bhatt, P. D., Carioto, J., Pyenson, B., & Burgel, P. R. (2025). Impact of Increased Use of Single-Inhaler Triple Therapies on COPD Exacerbation Rates, Mortality, and Total Costs: PROMETHEUS France. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s539055

Vancouver

Deslee G, Russo H, Fabry-Vendrand C, Koskas D, Thabut G, Bell JP, et al. Impact of Increased Use of Single-Inhaler Triple Therapies on COPD Exacerbation Rates, Mortality, and Total Costs: PROMETHEUS France. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s539055

BibTeX
@article{Deslee2025,
  author = {Deslee, Gaëtan and Russo, Héloïse and Fabry-Vendrand, Caroline and Koskas, David and Thabut, Gabriel and Bell, John P and Caplen, Melissa and Bhatt, Prachi Devendra and Carioto, Jennifer and Pyenson, Bruce and Burgel, Pierre-Régis},
  title = {Impact of Increased Use of Single-Inhaler Triple Therapies on COPD Exacerbation Rates, Mortality, and Total Costs: PROMETHEUS France},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2025},
  doi = {10.2147/copd.s539055}
}
Kostenlos starten →